Luca Arecco Shares ESMO Panel Consensus on Extended Endocrine Therapy in HR+ HER2- Breast Cancer

Luca Arecco, Clinical Research Fellow at ESMO, posted on X:

“ESMO Breast consensus.

Question: What is your recommended #extended adjuvant endocrine therapy for a woman aged 37-y with luminal B-like (G3 high Ki67 / RS) HR+ HER2- BC?

More than half of panelists would give extended OFS with higher nodal involvement (>5 N+).”